Volume 26, Number 11—November 2020
Research
Three Patients with COVID-19 and Pulmonary Tuberculosis, Wuhan, China, January–February 2020
Table
Characteristics | Patient 1 | Patient 2 | Patient 3 |
---|---|---|---|
Age, y | 50 | 44 | 57 |
Smoker | + | + | – |
Underlying medical conditions† |
– |
+ |
+ |
Signs and symptoms‡ | |||
Fever | + | + | + |
Cough | + | + | + |
Fatigue | + | + | + |
Wheeze | + | + | + |
Chills | – | + | – |
Weight loss | + | + | + |
Night sweats | NA | + | – |
Vomiting | – | – | – |
Diarrhea | – | – | – |
Tachycardia | – | + | – |
Tachypnoea |
+ |
– |
+ |
Laboratory findings§ | |||
Leukocyte count, × 109 cells/L (reference range 3.5–9.5 × 109 cells/L) | 10.4 (↑) | 6.86 | 8.86 |
Neutrophil count, ×109 cells/L (reference range 1.8–6.3 × 109 cells/L) | 8.74 (↑) | 4.35 | 7.74 (↑) |
Lymphocyte count ×109 cells/L (reference range 1.1–3.2 × 109 cells/L) | 0.73 (↓) | 1.75 | 0.74 (↓) |
T-cell count, cells/μL (reference range 690–2,540 cells/μL) | NA | 1,092.92 | 282.12 (↓) |
CD4+ T-cell percentage (reference range 40%–57%) | NA | 25.3 (↓) | 25.91 (↓) |
CD4+ T-cell count, cells/μL (reference range 410–1,590 cells/μL) | NA | 415.51 | 138.91 (↓) |
CD8+ T-cell percentage (reference range 8%–37%) | NA | 36.67 | 19.37 |
CD8+ T-cell count, cells/μL (reference range 190–1,140 cells/μL) | NA | 602.14 | 103.8 (↓) |
CD4+ to CD8+ T-cell count ratio (reference range 0.71–2.78) | NA | 0.69 (↓) | 1.34 |
Hemoglobin, g/L (reference range 130–175 g/L) | 83 (↓) | 127 (↓) | 134 |
Platelet count, ×109/L (reference range 125–350 109/L) | 430 (↑) | 280 | 218 |
Activated partial thromboplastin time, s (reference range 27–45 s) | 45.5 (↑) | 36.4 | 30.8 |
Prothrombin time, s (reference range 11–16 s) | 18.4 (↑) | 13.3 | 16.29 |
International normalized ratio (reference range 0.8–1.3) | 1.44 (↑) | 1.03 | 1 |
Fibrinogen, g/dL (reference range 2–4 g/dL) | 8.01 (↑) | 4.5 (↑) | 5.07 (↑) |
D–dimer, μg/L (reference range 0–0.5 μg/L) | 1.58 (↑) | 3.7 (↑) | NA |
Alanine aminotransferase, U/L (reference range 9–50 U/L) | 9 | 12 | 52 (↑) |
Aspartate aminotransferase, U/L (reference range 15–40 U/L) | 3 (↓) | 11 (↓) | 45 (↑) |
Albumin, g/L (reference range 35–55 g/L) | 29.9 (↓) | 36.7 | 35.6 |
Bilirubin, μmol/L (reference range 0–21 μmol/L) | 2.56 | 5 | 4.15 |
Creatinine, μmol/L (reference range 44–115 μmol/L) | 38 (↓) | NA | 64 |
Lactate dehydrogenase, U/L (reference range 106–245 U/L) | 170 | NA | 367 (↑) |
Creatine kinase, U/L (reference range 24.0–194.0 U/L) | 31 | 24.7 | 45.1 |
Creatine kinase isoenzyme, U/L (reference range 0–24 U/L) | 9 | 12.6 | 22.6 |
Bicarbonate, mmol/L (reference range 22–27 mmol/L) | 21.4 | 29.9 (↑) | 29.8 (↑) |
C-reactive protein, mg/L (reference range 0.0–5.0 mg/L) | 293.8 (↑) | 3.99 | 44.4 (↑) |
Procalcitonin, ng/mL (reference range 0.00–0.25 ng/mL) | 0.14 | 0.04 | 0.04 |
Erythrocyte sedimentation rate, mm/h; (reference range 0–15 mm/h) |
123 (↑) |
81 (↑) |
53 (↑) |
Chest CT findings | |||
Ground-glass opacities | + | + | + |
Pleural effusion |
+ |
+ |
– |
Treatment | |||
Antibiotics | + | + | + |
Anti-TB therapy | + | + | – |
Lopinavir/ritonavir | – | + | + |
Umifenovir hydrochloride | – | + | – |
Interferon–α | – | + | + |
Corticosteroid | + | – | + |
Immunoglobulin | – | – | + |
Oxygen support | + | – | + |
Clinical course |
|||
Duration of hospitalization, d | 22 | 26 | 27 |
Time from illness onset to discharge or death, d |
35 |
47 |
46 |
Clinical severity | Severe | Moderate | Severe |
Outcome | Died | Survived | Survived |
*All patients were male. CT, computed tomography; NA, not available; TB, tuberculosis; ↑, values higher than reference range; ↓, values lower than reference range.; +, positive; –, negative. †Patients 2 and 3 had type 2 diabetes mellitus. ‡At admission to the original hospital. §Test results after transfer to the Wuhan Pulmonary Hospital.
1These first authors contributed equally to this article.
2These senior authors contributed equally to this article.
Page created: July 15, 2020
Page updated: October 19, 2020
Page reviewed: October 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.